1. Home
  2. BMEA vs UNB Comparison

BMEA vs UNB Comparison

Compare BMEA & UNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • UNB
  • Stock Information
  • Founded
  • BMEA 2017
  • UNB 1891
  • Country
  • BMEA United States
  • UNB United States
  • Employees
  • BMEA N/A
  • UNB N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • UNB Major Banks
  • Sector
  • BMEA Health Care
  • UNB Finance
  • Exchange
  • BMEA Nasdaq
  • UNB Nasdaq
  • Market Cap
  • BMEA 125.0M
  • UNB 117.7M
  • IPO Year
  • BMEA 2021
  • UNB 1998
  • Fundamental
  • Price
  • BMEA $2.15
  • UNB $24.99
  • Analyst Decision
  • BMEA Strong Buy
  • UNB
  • Analyst Count
  • BMEA 8
  • UNB 0
  • Target Price
  • BMEA $10.63
  • UNB N/A
  • AVG Volume (30 Days)
  • BMEA 658.3K
  • UNB 11.4K
  • Earning Date
  • BMEA 10-28-2025
  • UNB 10-15-2025
  • Dividend Yield
  • BMEA N/A
  • UNB 5.76%
  • EPS Growth
  • BMEA N/A
  • UNB N/A
  • EPS
  • BMEA N/A
  • UNB 2.01
  • Revenue
  • BMEA N/A
  • UNB $48,950,000.00
  • Revenue This Year
  • BMEA N/A
  • UNB N/A
  • Revenue Next Year
  • BMEA N/A
  • UNB N/A
  • P/E Ratio
  • BMEA N/A
  • UNB $12.43
  • Revenue Growth
  • BMEA N/A
  • UNB 2.99
  • 52 Week Low
  • BMEA $1.29
  • UNB $24.50
  • 52 Week High
  • BMEA $13.07
  • UNB $37.70
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 61.18
  • UNB 39.70
  • Support Level
  • BMEA $1.98
  • UNB $24.50
  • Resistance Level
  • BMEA $2.18
  • UNB $26.43
  • Average True Range (ATR)
  • BMEA 0.12
  • UNB 0.53
  • MACD
  • BMEA 0.01
  • UNB -0.07
  • Stochastic Oscillator
  • BMEA 75.76
  • UNB 24.02

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About UNB Union Bankshares Inc.

Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.

Share on Social Networks: